208 related articles for article (PubMed ID: 35054884)
21. Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior.
Yang J; Gong R; Ma Y; Gao J; Li Z; Zhu J; Gong Y
Front Endocrinol (Lausanne); 2021; 12():654638. PubMed ID: 33897621
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
23. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
24. Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.
Xie W; Zeng Y; Hu L; Hao J; Chen Y; Yun X; Lin Q; Li H
Front Immunol; 2022; 13():991656. PubMed ID: 36211409
[TBL] [Abstract][Full Text] [Related]
25. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
[TBL] [Abstract][Full Text] [Related]
26. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
27. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
28. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
[TBL] [Abstract][Full Text] [Related]
29. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
30. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome.
Wong KS; Dong F; Telatar M; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Afkhami M; Barletta JA
Thyroid; 2021 Jun; 31(6):933-940. PubMed ID: 33143568
[No Abstract] [Full Text] [Related]
31. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
32. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma.
Liu F; Yin R; Chen X; Chen W; Qian Y; Zhao Y; Jiang Y; Ma D; Hu T; Yu T; Zhu Y; Zhang Y
Biomed Pharmacother; 2019 Jun; 114():108605. PubMed ID: 30904818
[TBL] [Abstract][Full Text] [Related]
33. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
34. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
35. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
36. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
37. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
38. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
39. CRLF1-MYH9 Interaction Regulates Proliferation and Metastasis of Papillary Thyroid Carcinoma Through the ERK/ETV4 Axis.
Yu ST; Sun BH; Ge JN; Shi JL; Zhu MS; Wei ZG; Li TT; Zhang ZC; Chen WS; Lei ST
Front Endocrinol (Lausanne); 2020; 11():535. PubMed ID: 32982961
[TBL] [Abstract][Full Text] [Related]
40. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
Liu M; Chen P; Hu HY; Ou-Yang DJ; Khushbu RA; Tan HL; Huang P; Chang S
J Cancer Res Clin Oncol; 2021 Feb; 147(2):323-337. PubMed ID: 33387037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
